Document Detail

Pleiotropic effects of inhibitors of the RAAS in the diabetic population: above and beyond blood pressure lowering.
MedLine Citation:
PMID:  20425064     Owner:  NLM     Status:  MEDLINE    
Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are indispensable therapeutic agents for treating hypertension and proteinuria in patients with diabetes mellitus. Studies have shown that the renin-angiotensin-aldosterone system (RAAS) has effects on various organ systems, including the central nervous system, heart, and kidneys. Angiotensin II has major deleterious effects on vascular compliance, vascular relaxation, and plasma markers of inflammation, which are surrogate markers of cardiovascular disease. Evidence is established from major trials that ACE inhibitors and ARB therapy improve these surrogate markers and reduce cardiovascular disease, renal disease, and stroke. Accumulating evidence also supports the newer class of medication, the direct renin inhibitor aliskiren, as beneficial in hypertensive persons with diabetes mellitus. In this article, we review the mechanisms through which inhibitors of the RAAS benefit persons with hypertension and decrease the development of cardiovascular and renal disease above and beyond blood pressure lowering.
Haisam Ismail; Rena Mitchell; Samy I McFarlane; Amgad N Makaryus
Related Documents :
14675884 - Effect of statin therapy added to ace-inhibitors on blood pressure control and endothel...
12002704 - Ace inhibition is superior to angiotensin receptor blockade for renography in renal art...
7646844 - Prevention of endothelial dysfunction in small and large arteries in a model of chronic...
12701984 - Initial findings of the aask: african americans with hypertensive kidney disease benefi...
282054 - An altered relation between arterial pressure and plasma angiotensin ii concentration r...
9530214 - Peroxynitrite-mediated vasorelaxation: evidence against the formation of circulating s-...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current diabetes reports     Volume:  10     ISSN:  1539-0829     ISO Abbreviation:  Curr. Diab. Rep.     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-04-28     Completed Date:  2010-09-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101093791     Medline TA:  Curr Diab Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  32-6     Citation Subset:  IM    
Department of Cardiology, North Shore University Hospital, 300 Community Drive, Manhasset, NY 11030, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antihypertensive Agents / pharmacology*,  therapeutic use*
Blood Pressure / drug effects*
Diabetes Complications / drug therapy,  physiopathology
Diabetes Mellitus / drug therapy*,  physiopathology
Hypertension / drug therapy,  etiology,  physiopathology
Renin-Angiotensin System / drug effects*
Reg. No./Substance:
0/Antihypertensive Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Does choice of antidiabetes therapy influence macrovascular outcomes?
Next Document:  The emerging role of biomarkers in diabetic and hypertensive chronic kidney disease.